UNBELIEVABLE: 3 - The Untold Story

Nuclear, Pharma & Travel Buybacks: Confident or Cautious Signals?

Nuclear, pharma, and travel giants just made significant buyback announcements. However, not all of these are as confidence-inspiring as they may seem.

MarketBeat · Apr 6

Novo Nordisk Just Announced Wegovy Subscriptions. Does That Make NVO Stock a Buy?

Wegovy subscriptions may create interest, but there is a major threat looming for Novo Nordisk.

Barchart · Apr 2

Eli Lilly’s Employer Push Could Unlock New GLP-1 Demand

Eli Lilly is launching Employer Connect to expand Zepbound access while its oral GLP-1 orforglipron just topped Novo Nordisk's Rybelsus in a head-to-head trial.

MarketBeat · Mar 15

US health company launches weight-loss pill that Novo Nordisk calls an 'untested knockoff'

The American telehealth company announced the launch of a compounded weight-loss pill for €41, drawing criticism from Novo Nordisk, the Danish company behind the weight-loss drug Wegovy, which called the product an “untested knockoff.”

Euronews · Feb 6

Hims & Hers launches copy of Wegovy pill, prompting legal threats from drugmaker Novo Nordisk

Telehealth company Hims & Hers is launching a cheaper, off-brand version of the blockbuster weight loss pill Wegovy

The Independent UK · Feb 5

The Metabolic Split: Why Eli Lilly Soars as Novo Stumbles

Eli Lilly surges past the trillion-dollar mark as aggressive manufacturing expansion drives volume growth that eclipses rival Novo Nordisk in 2026.

MarketBeat · Feb 5

Novo Nordisk shares plunge on outlook warning as Mounjaro rival races ahead

Wegovy and Ozempic maker Novo Nordisk forecast plunging sales and earnings in 2026, which saw the Danish drugmaker’s shares plummet by nearly a fifth.

Evening Standard · Feb 4

Wegovy and Ozempic maker forecasts sharp drop in revenue for 2026

Novo Nordisk share price plunges after blaming lower US drug prices, patent protection issues and rising competition

The Guardian - UK · Feb 4

Why Denmark can't use Ozempic as a trump card with the US in Greenland talks

Novo Nordisk, the Danish manufacturer of weight-loss drugs Ozempic and Wegovy, has a large market share in the US. But it's not enough to put pressure on US President Donald Trump's administration during Greenland talks, experts say.

Euronews · Feb 2

The New Wegovy Pill Is Already Popular. Does That Make Novo Nordisk Stock a Buy for Q1?

Novo Nordisk entered 2026 with fresh momentum after the U.S. launch of its oral Wegovy pill. Is the stock a buy now?

Barchart · Jan 21